Thomas P. Graham Jr. Division of Cardiology
The Thomas P. Graham Jr. Division of Cardiology is a leader in cardiac care for children and young adults throughout the United States. Our nationally recognized staff and state-of-the-art facilities enable us to provide diagnosis and management of a full spectrum of heart problems in infants, children, and adults with congenital and acquired heart disease. Our location at the Children's Hospital enables the division to take advantage of the broad range of clinical, ancillary, and research programs offered through the Pediatric Heart Institute as well as the Vanderbilt University Medical Center.

Through the close cooperation of the Pediatric Heart Institute and the adult Vanderbilt Heart and Vascular Institute, an interdisciplinary group of physicians and staff are dedicated to the care of patients with heart disease. This team is focused on the complex interactions of congenital and acquired heart disease resulting in unique and individualized medical and surgical therapies.

Areas of particular interest and expertise within the Pediatric Heart Institute include Cardiac Anesthesia, Cardiac Imaging, Cardiac Catheterization, Electrophysiology, and Fetal Heart Services. In addition, our Pediatric Heart Transplant program is the fifth largest transplant program in the country and the only program of its kind in the state, and our Pediatric Pulmonary Hypertension program is the only comprehensive multidisciplinary program in the entire Southeast. The Genetics of Congenital Heart Defects Program, in partnership with Adult Cardiology, is the only program of its kind in the Mid-Atlantic and the Southeast; the goal is to make sure young adults transition into the Adult Congenital Heart Defect Program for lifelong follow-up.

Led by the division chief, H. Scott Baldwin, M.D., our board-certified faculty members are at the forefront of research efforts. Dr. Baldwin is a principle investigator in the SysCode NIH Roadmap initiative, which focuses on harnessing the potential of normal developmental processes to inform the creation of tissue-engineered organs. Other research interests include the first large, multi-center trial of Citrupress, which is an intravenous form of citrulline, developed at Vanderbilt.  It is being used to treat postoperative pulmonary hypertension following heart surgery.  In addition, Vanderbilt and the Pediatric Heart Institute were added as an ancillary site for the Pediatric Heart Network's (PHN) Marfan trial which was created and funded by the National Heart, Lung and Blood Institute.


  • To develop new methods of diagnosing and treating congenital and acquired cardiac malformations.
  • To prepare the next generation of physicians to practice the clinical science of Pediatric Cardiology and to develop expertise in clinical or basic research.